Markman M, Howell S B, Lucas W E, Pfeifle C E, Green M R
J Clin Oncol. 1984 Dec;2(12):1321-6. doi: 10.1200/JCO.1984.2.12.1321.
Thirty-one patients with refractory ovarian cancer and other malignancies principally confined to the abdominal cavity were treated with an intraperitoneal combination-chemotherapy regimen consisting of cisplatin (100 to 200 mg/m2), cytosine arabinoside (10(-4) to 10(-3) mol/L) and doxorubicin (2 to 18 mumol/L). Sodium thiosulfate was simultaneously administered intravenously to prevent cisplatin-induced nephrotoxicity. Eight of 26 evaluable patients demonstrated clinical response including seven of 17 (41%) with ovarian cancer refractory to frontline chemotherapy. Systemic toxicity was mild except for nausea and vomiting. Abdominal pain secondary to doxorubicin was the major complication of therapy. We conclude that combination intraperitoneal therapy with cisplatin, cytosine arabinoside, and doxorubicin can be safely administered with objective tumor responses observed in patients with ovarian cancer heavily pretreated and in individuals with other malignancies involving the peritoneal cavity. Doxorubicin-induced local pain limits the ability to administer multiple courses of this treatment regimen.
31例难治性卵巢癌及其他主要局限于腹腔的恶性肿瘤患者接受了腹腔内联合化疗方案，该方案由顺铂（100至200mg/m²）、阿糖胞苷（10⁻⁴至10⁻³mol/L）和多柔比星（2至18μmol/L）组成。同时静脉注射硫代硫酸钠以预防顺铂引起的肾毒性。26例可评估患者中有8例出现临床反应，其中17例卵巢癌患者中有7例（41%）对一线化疗耐药。除恶心和呕吐外，全身毒性较轻。多柔比星引起的腹痛是治疗的主要并发症。我们得出结论，顺铂、阿糖胞苷和多柔比星联合腹腔内治疗可安全给药，在经过大量预处理的卵巢癌患者和涉及腹膜腔的其他恶性肿瘤患者中观察到客观的肿瘤反应。多柔比星引起的局部疼痛限制了该治疗方案多疗程给药的能力。
